Kilpest's molecular diagnostics business is a niche segment with strong potential. Market size is Rs 300+cr with huge growth potential. It has 10%+ market share. Co is cash-rich (Rs 151 cr) & will earn FCF of Rs 69 cr over the next three years. It is at a discount of ~51% to average P/E ratio of peers. Buy for 43% upside…
Kilpest has huge growth potential. Buy for 43% upside potential
| Subscribe To Our Free Newsletter |
